(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 1.25% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Illumina's revenue in 2025 is $4,337,000,000.On average, 6 Wall Street analysts forecast ILMN's revenue for 2025 to be $668,838,712,200, with the lowest ILMN revenue forecast at $667,369,055,000, and the highest ILMN revenue forecast at $670,875,400,000. On average, 6 Wall Street analysts forecast ILMN's revenue for 2026 to be $695,661,697,400, with the lowest ILMN revenue forecast at $685,755,600,000, and the highest ILMN revenue forecast at $705,384,800,000.
In 2027, ILMN is forecast to generate $750,948,922,200 in revenue, with the lowest revenue forecast at $737,519,700,000 and the highest revenue forecast at $762,901,522,000.